International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance)

被引:0
作者
Levtchenko, Elena [1 ]
Ariceta, Gema [2 ]
Arguedas Flores, Olga [3 ]
Bichet, Daniel G. [4 ]
Bockenhauer, Detlef [5 ,6 ,7 ,8 ]
Emma, Francesco [9 ]
Hoorn, Ewout J. [10 ]
Koster-Kamphuis, Linda [11 ]
Nijenhuis, Tom [12 ]
Trepiccione, Francesco [13 ,14 ]
Vargas-Poussou, Rosa [15 ]
Walsh, Stephen B. [16 ]
Knoers, Nine V. A. M. [17 ]
机构
[1] Amsterdam Univ Med Ctr, Emma Childrens Hosp, Dept Paediat Nephrol, Amsterdam, Netherlands
[2] Autonomous Univ Barcelona, Hosp Vall dHebron, Paediat Nephrol Dept, Barcelona, Spain
[3] Univ Amsterdam, Med Ctr, Emma Childrens Hosp, Amsterdam, Netherlands
[4] Univ Montreal, Serv Nephrol, Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada
[5] Catholic Univ Leuven Radiol, Univ Hosp, Louvain, Belgium
[6] Katholieke Univ Leuven, Leuven, Belgium
[7] Univ Coll London Hosp NHS Fdn Trust, London, England
[8] UCL, London, England
[9] Bambino Gesu Childrens Hosp IRCCS, Div Nephrol, Rome, Italy
[10] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Internal Med, Div Nephrol & Transplantat, Rotterdam, Netherlands
[11] Radboud Univ Nijmegen, Med Ctr, Amalia Childrens Hosp, Nijmegen, Netherlands
[12] Radboud Univ Nijmegen Med Ctr, Dept Nephrol, Nijmegen, Netherlands
[13] Univ Campania Luigi Vanvitelli, Dept Med Translat Sci, Naples, Italy
[14] BIOGEM Inst Mol Biol & Genet, Ariano Irpino, Italy
[15] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Ctr Specialise Obes, Serv Nutr, Paris, France
[16] UCL, London Tubular Ctr, Dept Renal Med, London, England
[17] Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands
关键词
V2 RECEPTOR MUTANTS; PHOSPHODIESTERASE INHIBITOR; PHARMACOLOGICAL CHAPERONES; DIFFERENTIAL-DIAGNOSIS; MEMBRANE INSERTION; X-INACTIVATION; HYDROCHLOROTHIAZIDE; COPEPTIN; INDOMETHACIN; AMILORIDE;
D O I
10.1038/s41581-024-00897-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Congenital nephrogenic diabetes insipidus (NDI; also known as arginine vasopressin resistance) is a rare inherited disorder of water homeostasis, caused by insensitivity of the distal nephron to arginine vasopressin. Consequently, the kidney loses its ability to concentrate urine, which leads to polyuria, polydipsia and the risk of hypertonic dehydration. The diagnosis and management of NDI are very challenging and require an integrated, multidisciplinary approach. Here, we present 36 recommendations for diagnosis, treatment and follow-up in both children and adults, as well as emergency management, genetic counselling and family planning, for patients with NDI. These recommendations were formulated and graded by an international group of experts in NDI from paediatric and adult nephrology, urology and clinical genetics from the European Rare Kidney Disease Reference Network and the European Society of Paediatric Nephrology, as well as patient advocates, and were validated by a voting panel in a Delphi process. The goal of these recommendations is to provide guidance to health care professionals who care for patients with NDI and to patients and their families. In addition, we emphasize the need for further research on different aspects of this potentially life-threatening disorder to support the development of evidence-based guidelines in the future. Congenital nephrogenic diabetes insipidus is a rare but potentially life-threatening condition. This Consensus Statement provides clinical practice recommendations developed by the European Reference Network on Rare Kidney Diseases, the European Society for Paediatric Nephrology and patient advocates to support clinicians in the diagnosis, treatment and genetic counselling of children and adults with nephrogenic diabetes insipidus.
引用
收藏
页码:83 / 96
页数:14
相关论文
共 103 条
  • [1] Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
    Aihara, Makoto
    Lu, Fenghe
    Kawata, Hisashi
    Tanaka, Yuki
    Yamamura, Kenzo
    Odani-Kawabata, Noriko
    Shams, Naveed K.
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2019, 35 (10) : 542 - 550
  • [2] Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
    Aihara, Makoto
    Lu, Fenghe
    Kawata, Hisashi
    Iwata, Akihiro
    Liu, Kathy
    Odani-Kawabata, Noriko
    Shams, Naveed K.
    [J]. JOURNAL OF GLAUCOMA, 2019, 28 (05) : 375 - 385
  • [3] HYDROCHLOROTHIAZIDE-AMILORIDE IN THE TREATMENT OF CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS
    ALON, U
    CHAN, JCM
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 1985, 5 (01) : 9 - 13
  • [4] [Anonymous], 2003, Salt and health
  • [5] Nephrogenic diabetes insipidus: the key element of paradoxical hyponatremia
    Anton-Gamero, Montserrat
    Garcia-Martinez, Elena
    Fernandez-Ramos, Joaquin
    Rodriguez-Salas, Monica
    Gil-Campos, Mercedes
    [J]. PEDIATRIC NEPHROLOGY, 2009, 24 (11) : 2277 - 2278
  • [6] Arima H, 2022, ENDOCR J, V69, P1281, DOI [10.1210/clinem/dgac547, 10.1507/endocrj.EJ20220831]
  • [7] Arthus MF, 2000, J AM SOC NEPHROL, V11, P1044, DOI 10.1681/ASN.V1161044
  • [8] Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus
    Bernier, Virginie
    Morello, Jean-Pierre
    Zarruk, Alexandro
    Debrand, Nicolas
    Salahpour, Ali
    Lonergan, Michle
    Arthus, Marie-Francoise
    Laperriere, Andre
    Brouard, Remi
    Bouvier, Michel
    Bichet, Daniel G.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (01): : 232 - 243
  • [9] Bichet D. G., 2023, EVALUATION PATIENTS
  • [10] GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus
    Bichet, Daniel G.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 183 (02) : R29 - R40